Roth Capital Starts Calyxt Inc. (CLXT) at Buy

November 2, 2021 8:25 AM EDT
Get Alerts CLXT Hot Sheet
Price: $0.17 -10.53%

Rating Summary:
    5 Buy, 6 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 6 | Down: 13 | New: 58
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Roth Capital analyst Brian White initiates coverage on Calyxt Inc. (NASDAQ: CLXT) with a Buy rating and a price target of $10.00.

The analyst comments "The first major catalyst for the shares should be the completion of the installation of the BioFactoryTM by the end of the fourth quarter. The next major milestones should be scaling up the production of Betanin in the BioFactoryTM to the 100 liter level. Our industry contacts indicated that projects that scale to 100 liters ultimately scale to industrial scale. We believe this proof-of-concept production at the BioFactoryTM will drive significant commercial partnership interest, which leads us to our next expected catalyst, the signing of a bio production agreement with an end market customer."

For an analyst ratings summary and ratings history on Calyxt Inc. click here. For more ratings news on Calyxt Inc. click here.

Shares of Calyxt Inc. closed at $3.69 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Roth Capital, Brian White